The Latest on the COVID-19 Vaccines
AstraZeneca (AZN): After pausing for more than a month, AZN is expected to resume its Phase 3 US study of its COVID-19 vaccine. The trial was paused after a patient, who received the vaccine, developed an illness suspected to be a serious spinal inflammatory condition known as transverse myelitis. The patient was . . .
This content is for paid subscribers.
Today’s Highlights
October 21, 2020
